NOTION-4: Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter bioprosthetic aortic valves.

Patients who have undergone successful transcatheter bioprosthetic aortic valve implantation (TAVI)

The number of patients with at least one prosthetic valve leaflet with HALT as assessed by cardiac CT at one year after TAVI.

The combined clinical endpoint of all-cause mortality, thromboembolic event, and life-threatening or major bleeding at 1 year, 3 years and 5 years after randomization, The number of patients with at least one prosthetic valve leaflet with HALT as assessed by cardiac CT at 3 months, 1, 3 and 5 years after TAVI, Number of prosthetic leaflets with HALT at CT-scan at 3 months, 1 year, 3 and 5 years., The clinical endpoint of ischemic stroke verified by cerebrovascular imaging after the TAVI-procedure in patients with vs. without HALT., Any type of stroke – including ischemic and hemorrhagic stroke, All-cause mortality, Cardiovascular mortality as defined in current VARC definition, Major bleeding or life-threatening bleeding, Need for re-intervention (valve-in-valve TAVI, paravalvular leak closure, SAVR), Aortic bioprosthetic dysfunction (according to EAPCI/ESC/EACTS definitions), Rate of bioprosthetic valve failure (according to EAPCI/ESC/EACTS definitions), NYHA classification, Quality of life scores

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Denmark